PRNewsWire
20 Aug 2026, 21:01 UTC · 2d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for adults as young as 40 experiencing cognitive impairment. — Broadening the eligible patient population to younger adults significantly expands the addressable market for Alzheimer's diagnostics and potential early-intervention treatments.
+0.60Biomarker integration has become standard in the industry, with 83% of active Alzheimer's clinical trials now incorporating them. — High biomarker adoption increases the probability of trial success by ensuring more accurate patient selection and target engagement verification.
+0.40The FDA has cleared three Alzheimer's blood tests in approximately one year, including PrecivityAD2 and Fujirebio's Lumipulse. — Rapid regulatory acceleration indicates a shifting paradigm toward scalable, blood-based diagnostics over more invasive or expensive methods like PET scans.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1d ago
